外科領域におけるSulfamethoxazole-Trimethoprim合剤の臨床試用成績について

抄録

We have attempted to assess the therapeutic efficacy of sulfamethoxazole (SMX) -trimethoprim (TMP) combination product according to the criteria established by the Japan Society of Chemotherapy for the evaluation of antimicrobial agents. It was difficult, however, to follow up the changes in leukocyte counts and results of bacteriological studies because the clinical materials were limited to anbulatory out-patients. The therapeutic response may also be significantly influenced by such factor as surgical incision. Accordingly, our clinical assessment had to largely rely upon the improvement in local inflammatory manifestations. Our clinical experience indicates that SMX-TMP combination product is a new effective antimicrobial agent for the treatment of acute soft part infections.